Cancer Epigenetics
Cancer epigenetics is the study of epigenetic mutations in the DNA of cancer cells that do not involve genetic sequence modification, but rather involves mutations in the way genetic code is expressed. Epigenetic processes are required to maintain normal tissue specific gene expression sequence and are essential for normal development. They may be equally important, or even more important, than the genetic mutation in a cell. Disruption of epigenetic processes in cancer, can lead to a loss of gene expression that occurs about 10 times by documentation rather than mutation.
Related Conference of Cancer Epigenetics
September 24-25, 2026
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
Paris, France
November 16-17, 2026
19th International Conference on Human Genomics and Genomic Medicine
Tokyo, Japan
Cancer Epigenetics Conference Speakers
Recommended Sessions
- Biomarkers
- Cancer Epigenetics
- Cardiovascular Proteomics
- Clinical Genomics & Clinical Proteomics
- Computational Biology, Bioinformatics, and Biostatistics
- Computing in Biomedicine and Genomics
- E-Health, Telemedicine
- Genome Projects and Genome Sequencing
- Immunogenetics and Immunology
- Metabolomics and Metabonomics
- Metabolomics in Precision Medicine
- Modern Genetics
- Pharmacogenomics
- Protein Interactions in Biology
- Proteomics and Genomics
- Proteomics and its Medicinal Research
- Proteomics Technologies
- Signaling/Computational Biomedical Data Engineering
- Stem Cell Proteomics
- Toxicogenomics and Pharmacoproteomics
- Transcriptomics
Related Journals
Are you interested in
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)

